Products and clincal projects

Drugs on the market:
Eligard®
Veregen®(Polyphenon E® Ointment)

Projects in clinical development:
EndoTAG®-1
RhuDexTM
Oncolytic viruses (HSV)

Technologies:
EndoTAG®
Oncolytic viruses (HSV)

Projects in Clinical Development

Product Indication Preclinic/
Research
Clinical Phase Approval Marketed
  I II III  
 Eligard® 1)
 Veregen® (Polyphenon
 E Ointment) ® 2)
Genital Warts
  Actinic Keratosis 3)  
 
     
 EndoTAG®-1 Pancreatic Cancer    
  Breast Cancer  
 
     
  Additional solid tumors          
 RhuDex® Rh. Arthritis  
 
     
 oHSV (NV1020) Colon Liver Metastases  
 
     
Chance of reaching the market4 10-30% 30-60% 60-80% 80-90%
 

1 European marketing rights acquired from QLT USA Inc.(formerly Atrix). Marketing partnership with Astellas Pharma Ltd.
2 Marketing partnership with Nycomed for the US market und Juste S.A.Q.F., for Spain and Portugal.
3 Precursors of a specific kind of skin cancer.
4 Industrial average, source: Ernst&Young, 2009.